Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

Michael D. Prados, Susan M. Chang, Nicholas Butowski, Rebecca Deboer, Rupa Parvataneni, Hannah Carliner, Paul Kabuubi, Jennifer Ayers-Ringler, Jane Rabbitt, Margaretta Page, Anne Fedoroff, Penny K. Sneed, Mitchel S. Berger, Michael W. McDermott, Andrew T. Parsa, Scott Vandenberg, C. David James, Kathleen R. Lamborn, David Stokoe, Daphne A. Haas-Kogan

Research output: Contribution to journalArticlepeer-review

298 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Agricultural and Biological Sciences